BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 15720252)

  • 1. Peripheral arterial disease: a missed opportunity to administer statins so as to reduce cardiac morbidity and mortality.
    Daskalopoulou SS; Daskalopoulos ME; Liapis CD; Mikhailidis DP
    Curr Med Chem; 2005; 12(4):443-52. PubMed ID: 15720252
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statins and peripheral arterial disease: effects on claudication, disease progression, and prevention of cardiovascular events.
    Coppola G; Novo S
    Arch Med Res; 2007 Jul; 38(5):479-88. PubMed ID: 17560452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering.
    Pedersen TR
    Am J Cardiovasc Drugs; 2010; 10 Suppl 1():10-7. PubMed ID: 21391729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statins and peripheral arterial disease: potential mechanisms and clinical benefits.
    Alnaeb ME; Alobaid N; Seifalian AM; Mikhailidis DP; Hamilton G
    Ann Vasc Surg; 2006 Sep; 20(5):696-705. PubMed ID: 16841271
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal medical management of peripheral arterial disease.
    Rice TW; Lumsden AB
    Vasc Endovascular Surg; 2006; 40(4):312-27. PubMed ID: 16959725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of intensified lipid-lowering therapy on long-term prognosis in patients with peripheral arterial disease.
    Feringa HH; Karagiannis SE; van Waning VH; Boersma E; Schouten O; Bax JJ; Poldermans D
    J Vasc Surg; 2007 May; 45(5):936-43. PubMed ID: 17360142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
    Evans M; Roberts A; Davies S; Rees A
    Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Undertreatment of dyslipidemia in peripheral arterial disease and other high-risk populations: an opportunity for cardiovascular disease reduction.
    Hirsch AT; Gotto AM
    Vasc Med; 2002; 7(4):323-31. PubMed ID: 12710848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 2017 Taiwan lipid guidelines for high risk patients.
    Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
    J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statins and peripheral arterial disease.
    Markel A
    Int Angiol; 2015 Oct; 34(5):416-27. PubMed ID: 25410295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).
    Desai NR; Giugliano RP; Zhou J; Kohli P; Somaratne R; Hoffman E; Liu T; Scott R; Wasserman SM; Sabatine MS
    J Am Coll Cardiol; 2014 Feb; 63(5):430-3. PubMed ID: 24161333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HDL-C: role as a risk modifier.
    Barter P
    Atheroscler Suppl; 2011 Nov; 12(3):267-70. PubMed ID: 22152280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
    Daskalopoulou SS; Mikhailidis DP
    Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks.
    McKenney JM
    Am J Cardiol; 2005 Aug; 96(4A):60E-66E. PubMed ID: 16098846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Dyslipemia in diabetics treated with statins. Results of the DYSIS study in Spian].
    Millán J; Alegría E; Guijarro C; Lozano JV; Vitale GC; González-Timón B; González-Juanatey JR
    Med Clin (Barc); 2013 Nov; 141(10):430-6. PubMed ID: 23246165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis.
    Law MR; Wald NJ; Rudnicka AR
    BMJ; 2003 Jun; 326(7404):1423. PubMed ID: 12829554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Managing dyslipidemia in the high-risk patient.
    Stein EA
    Am J Cardiol; 2002 Mar; 89(5A):50C-57C. PubMed ID: 11900720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statins and infrainguinal vascular bypass procedures.
    Paraskevas KI; Giannoukas AD; Mikhailidis DP
    Curr Vasc Pharmacol; 2013 Jan; 11(1):51-7. PubMed ID: 23391423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pleiotropic effects of statins: evidence for benefits beyond LDL-cholesterol lowering.
    Marzilli M
    Am J Cardiovasc Drugs; 2010; 10 Suppl 1():3-9. PubMed ID: 21391728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The benefit of statins in non-cardiac vascular surgery patients.
    Stalenhoef AF
    J Vasc Surg; 2009 Jan; 49(1):260-5. PubMed ID: 19174265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.